Hemostemix Inc. (HEM.V)
CAD 0.1
(26.67%)
CAD 0.1
(26.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.33 Million CAD | 49.07% |
| 2022 | -4.58 Million CAD | 31.27% |
| 2021 | -6.66 Million CAD | 10.8% |
| 2020 | -7.47 Million CAD | -59.14% |
| 2019 | -4.69 Million CAD | 29.29% |
| 2018 | -6.64 Million CAD | -136.32% |
| 2017 | -2.81 Million CAD | 24.28% |
| 2016 | -3.71 Million CAD | 7.33% |
| 2015 | -4 Million CAD | 7.39% |
| 2014 | -4.32 Million CAD | -185.83% |
| 2013 | -1.51 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -364.09 Thousand CAD | -11.77% |
| 2024 Q1 | -325.74 Thousand CAD | 21.25% |
| 2023 Q1 | -1.13 Million CAD | -80.92% |
| 2023 Q4 | -413.64 Thousand CAD | -132.66% |
| 2023 Q3 | -177.78 Thousand CAD | 63.96% |
| 2023 FY | -2.15 Million CAD | 52.92% |
| 2023 Q2 | -493.25 Thousand CAD | 56.4% |
| 2022 Q1 | -1.33 Million CAD | 61.75% |
| 2022 FY | -4.58 Million CAD | 31.27% |
| 2022 Q2 | -1.58 Million CAD | -18.78% |
| 2022 Q3 | -1.03 Million CAD | 34.45% |
| 2022 Q4 | -625.31 Thousand CAD | 39.8% |
| 2021 Q2 | -1.4 Million CAD | -116.77% |
| 2021 Q4 | -3.48 Million CAD | -112.62% |
| 2021 Q1 | -647.23 Thousand CAD | 83.28% |
| 2021 Q3 | -1.64 Million CAD | -16.9% |
| 2021 FY | -6.66 Million CAD | 10.8% |
| 2020 FY | -7.47 Million CAD | -59.14% |
| 2020 Q4 | -3.87 Million CAD | -166.23% |
| 2020 Q3 | -1.45 Million CAD | 28.99% |
| 2020 Q2 | -2.04 Million CAD | -1614.71% |
| 2020 Q1 | -119.37 Thousand CAD | 78.45% |
| 2019 FY | -4.69 Million CAD | 29.29% |
| 2019 Q3 | -1.29 Million CAD | 0.91% |
| 2019 Q2 | -1.3 Million CAD | 13.38% |
| 2019 Q4 | -553.91 Thousand CAD | 57.21% |
| 2019 Q1 | -1.5 Million CAD | 23.93% |
| 2018 FY | -6.64 Million CAD | -136.32% |
| 2018 Q4 | -1.98 Million CAD | -27.72% |
| 2018 Q2 | -1.79 Million CAD | -37.31% |
| 2018 Q1 | -1.3 Million CAD | -310.75% |
| 2018 Q3 | -1.55 Million CAD | 13.64% |
| 2017 Q2 | -475.09 Thousand CAD | 11.68% |
| 2017 Q4 | 621.1 Thousand CAD | 121.6% |
| 2017 Q3 | -2.87 Million CAD | -505.33% |
| 2017 FY | -2.81 Million CAD | 24.28% |
| 2017 Q1 | -537.89 Thousand CAD | 37.27% |
| 2016 FY | -3.71 Million CAD | 7.33% |
| 2016 Q2 | -627.59 Thousand CAD | 5.33% |
| 2016 Q3 | -1.58 Million CAD | -152.2% |
| 2016 Q4 | -857.48 Thousand CAD | 45.82% |
| 2016 Q1 | -662.94 Thousand CAD | 43.89% |
| 2015 Q1 | -876.34 Thousand CAD | 60.04% |
| 2015 FY | -4 Million CAD | 7.39% |
| 2015 Q4 | -1.18 Million CAD | -19.55% |
| 2015 Q3 | -988.34 Thousand CAD | -3.13% |
| 2015 Q2 | -958.35 Thousand CAD | -9.36% |
| 2014 FY | -4.32 Million CAD | -185.83% |
| 2014 Q1 | -9519.00 CAD | 40.39% |
| 2014 Q3 | -833.7 Thousand CAD | -2142.1% |
| 2014 Q2 | -37.18 Thousand CAD | -290.63% |
| 2014 Q4 | -2.19 Million CAD | -163.05% |
| 2013 Q3 | -16.76 Thousand CAD | 52.62% |
| 2013 FY | -1.51 Million CAD | 0.0% |
| 2013 Q1 | -51.84 Thousand CAD | 0.0% |
| 2013 Q4 | -15.97 Thousand CAD | 4.76% |
| 2013 Q2 | -35.39 Thousand CAD | 31.73% |
| 2012 Q3 | - CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.35 Million CAD | 30.449% |
| Covalon Technologies Ltd. | -4.48 Million CAD | 48.018% |
| Universal Ibogaine Inc. | 497.15 Thousand CAD | 569.383% |
| Kane Biotech Inc. | -3.35 Million CAD | 30.495% |
| MedMira Inc. | -1.94 Million CAD | -20.018% |
| Marvel Biosciences Corp. | -2.31 Million CAD | -0.63% |
| NervGen Pharma Corp. | -17.77 Million CAD | 86.873% |
| XORTX Therapeutics Inc. | -6.38 Million CAD | 63.435% |